BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35993382)

  • 1. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
    Pal P; Zhang P; Poddar SK; Zheng G
    Expert Opin Ther Pat; 2022 Sep; 32(9):1003-1026. PubMed ID: 35993382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated patent review of Mcl-1 inhibitors (2020-2022).
    Liu J; Yin F; Wang Z; Song T; Zhang Z
    Expert Opin Ther Pat; 2023; 33(5):371-383. PubMed ID: 37293764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
    Modi V; Sankararamakrishnan R
    J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
    Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
    Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.
    Skwarska A; Konopleva M
    Cancer Res; 2023 Nov; 83(21):3501-3503. PubMed ID: 37824434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins.
    Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X
    J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
    Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
    Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
    Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
    Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
    Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
    Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 family inhibitors sensitize human cancer models to therapy.
    Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
    Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 is a clinically targetable vulnerability in breast cancer.
    Winder ML; Campbell KJ
    Cell Cycle; 2022 Jul; 21(14):1439-1455. PubMed ID: 35349392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.